A multicentric, non-randomized, open-label, non-comparative, active post-marketing surveillance study to evaluate the safety and efficacy of Sinarest Plus Suspension in children with common cold.

Sinarest Plus Suspension is a fixed dose combination of Paracetamol 250 mg, Phenylephrine Hydrochloride 5 mg, Chlorpheniramine Maleate 2 mg, Sodium citrate 60 mg and menthol 1 mg per 5 ml which is indicated for the treatment of common cold in children. The rationale behind this Active Post-Marketing Surveillance study is to document the efficacy and safety of Sinarest Plus Suspension for the treatment of common cold in children. Common cold of viral origin is a self-limiting disease which usually takes up to 10 days to cure by itself. Allergic rhinitis is nasal hypersensitivity symptoms persuaded by an immunologically mediated (predominantly IgE dependent) inflammation as mucous membrane gets exposed to allergens. The signs and symptoms of common cold overlaps with allergic rhinitis and show similar symptoms. According to the guidelines of DPHHS and Cochrane review combination of analgesic, antihistaminic and decongestant medication can be used for the treatment of common cold. Taking this into consideration we have initiated the Active Post-Marketing Surveillance study of Sinarest Plus Suspension in children of common cold.